IL206641B

A recombinant or isolated humanized or chimeric antibody, or antigen binding fragment thereof, that specifically binds to a neoepitope of human amyloid a peptide, a pharmaceutical composition comprising the antibody and its use in the preparation of a medicament for the treatment of amyloidosis

Abstract

This record has no abstract on file.

Term

No projected expiry on record.

  1. Priority
  2. Filed
  3. Published
  4. Today

70 members in 22 offices

This recordMember, by publication datePriority claim12 more offices are in the list below

Priority claims12

Priority claims
DocumentOfficeKindDate
754407United States of AmericaP
754407United States of AmericaP
9593208United States of AmericaP
9593208United States of AmericaP
2008088493United States of AmericaW
2008088493United States of AmericaW
61007544
61095932
PCTUS2008088493
US20070007544P
US20080095932P
WO2008US88493

Members70

Family members, oldest first
DocumentOfficeKind
AU2008345022A1AustraliaA1
CA2710984A1CanadaA1
WO2009086539A2World Intellectual Property Organization (WIPO)A2
US2009202432A1United States of AmericaA1
WO2009086539A3World Intellectual Property Organization (WIPO)A3
WO2009086539A4World Intellectual Property Organization (WIPO)A4
NO20101036LNorwayL
EP2237803A2European Patent Office (EPO)A2
IL206641D0IsraelD0
KR20110011596ARepublic of KoreaA
US2011038790A1United States of AmericaA1
EP2237803A4European Patent Office (EPO)A4
JP2011510913AJapanA
CN102016059AChinaA
US7928203B2United States of AmericaB2
US2011218328A1United States of AmericaA1
US2011224408A1United States of AmericaA1
CO6341486A2ColombiaA2
US2012039878A1United States of AmericaA1
HK1156365A1Hong Kong, ChinaA1
US2012189624A1United States of AmericaA1
US8268973B2United States of AmericaB2
NZ586875ANew ZealandA
US2012321555A1United States of AmericaA1
SG186689A1SingaporeA1
SG187504A1SingaporeA1
US8404815B2United States of AmericaB2
AU2013205096A1AustraliaA1
US8636981B2United States of AmericaB2
JP2014080434AJapanA
EP2730659A2European Patent Office (EPO)A2
US2014134103A1United States of AmericaA1
US8791243B2United States of AmericaB2
IL232956D0IsraelD0
CN102016059BChinaB
AU2008345022B2AustraliaB2
JP5730020B2JapanB2
US2015158937A1United States of AmericaA1
EP2237803B1European Patent Office (EPO)B1
ES2544679T3SpainT3
DK2237803T3DenmarkT3
PT2237803EPortugalE
AU2015249034A1AustraliaA1
AU2013205096B2AustraliaB2
PL2237803T3PolandT3
JP2016003233AJapanA
EP2730659A3European Patent Office (EPO)A3
KR101603076B1Republic of KoreaB1
HUE025560T2HungaryT2
EA201070812A1Eurasian Patent Organization (EAPO)A1
US2017081396A1United States of AmericaA1
AU2015249034B2AustraliaB2
EA201790858A2Eurasian Patent Organization (EAPO)A2
AU2017248481A1AustraliaA1
EA028356B1Eurasian Patent Organization (EAPO)B1
EA201790858A3Eurasian Patent Organization (EAPO)A3
CA2710984CCanadaC
US2018360934A1United States of AmericaA1
IL206641AIsraelA
IL206641BThis recordIsraelB
IL232956AIsraelA
IL232956BIsraelB
AU2017248481B2AustraliaB2
EP3693470A1European Patent Office (EPO)A1
EA036059B1Eurasian Patent Organization (EAPO)B1
BRPI0821949A2BrazilA2
US2021008185A1United States of AmericaA1
BRPI0821949B1BrazilB1
MX384227BMexicoB
US2025268999A1United States of AmericaA1